Physician profile
Charleigh Arnold
NPI 1801250881
$1,325.89
in general payments reported to CMS, 2019-2025
25 companies · $90.20 in 2025
The $90.20 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $26.21 · 2021: $245 · 2022: $211 · 2023: $437 · 2024: $317 · 2025: $90.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $356.97 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $192.35 | 2021-2024 | Spravato, Xarelto |
| Abbvie INC. | $106.13 | 2022-2025 | Vraylar |
| Daiichi Sankyo INC. | $76.40 | 2021-2022 | |
| Corium, LLC | $74.63 | 2023-2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $72.73 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.53 | 2021-2024 | Trintellix |
| Lilly USA, LLC | $46.91 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.35 | 2025 | Caplyta |
| La Jolla Pharmaceutical Company | $30.95 | 2023 | Giapreza, Xerava |
| Novo Nordisk INC | $29.33 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $28.93 | 2021 | |
| Grifols USA, LLC | $21.09 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.13 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $20.12 | 2023 | Auvelity |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $18.33 | 2023 | |
| Shield Therapeutics INC | $17.54 | 2023 | Accrufer |
| Glaxosmithkline, LLC. | $15.46 | 2023 | Arexvy, Shingrix |
| Radius Health, INC. | $14.77 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.55 | 2022 | |
| Merck Sharp & Dohme LLC | $14.47 | 2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Horizon Therapeutics Plc | $13.76 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.18 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.84 | 2022 | |
| Allergan, INC. | $11.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charleigh Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.